What Are Protein-Protein Interactions (PPIs)?

Protein-protein interactions (PPIs) refer to the physical contact between two or more protein molecules. These interactions are often specific and transient and form the basis of almost every biological process. PPIs shape how cells respond to signals, replicate, divide, and even die. They can be stable, forming structural complexes like the ribosome or dynamic, as seen in signalling pathways.

Proteins interact through defined regions called binding interfaces. These regions comprise complementary surfaces, such as hydrophobic patches, hydrogen bonds, and electrostatic attractions. Disruption or modification of these interactions can lead to diseases. Therefore, targeting PPIs has become a key strategy in drug discovery.

Biological Functions Regulated by PPIs

PPIs in Signal Transduction Pathways

PPIs are the cornerstone of intracellular signalling. Ligand binding to cell-surface receptors often triggers a cascade of protein interactions. These include kinases, scaffolding proteins, and second messengers. For instance, the MAPK pathway involves sequential protein phosphorylation through direct interactions. Errors in such signalling cascades frequently contribute to cancer and other chronic diseases.

Protein Complexes in Transcription and Gene Regulation

Transcription factors must often bind co-activators or repressors to modulate gene expression. These complexes are formed via PPIs. For example, the interaction between the TATA-binding protein and other transcription machinery components is essential for RNA polymerase recruitment. Similarly, chromatin remodelling relies on multiprotein complexes that orchestrate DNA accessibility.

PPIs in Apoptosis and Cell Cycle Control

Apoptosis—the programmed cell death—is tightly regulated by pro-apoptotic and anti-apoptotic proteins. The BCL-2 family is a well-known example of a PPI dictating cell fate. Proteins like BAX and BAK require dimerization to permeabilize the mitochondrial membrane. Conversely, BCL-2 and BCL-xL inhibit this process through binding. Misregulation of these interactions often leads to uncontrolled cell proliferation.

Protein Interactions in Host-Pathogen Dynamics

Pathogens exploit host PPIs to establish infection. Viruses, in particular, encode proteins that mimic or disrupt host-protein interactions. For instance, HIV-1 integrates into host DNA through interactions between viral integrase and host cofactors. Understanding these interactions provides valuable insights for antiviral strategies.

PPIs as Therapeutic Targets

PPIs are increasingly recognized as critical nodal points in disease pathways. Small molecules or biologics that disrupt pathogenic PPIs can restore normal cellular function. Below are primary subdomains where PPIs have been targeted therapeutically, with representative examples and corresponding primary references.

Targeting Oncogenic Protein Complexes in Cancer

Cancer cells frequently depend on aberrant PPIs to sustain survival and proliferation. Two well-validated targets in this category are the MDM2-p53 interaction and anti-apoptotic BCL-2 family complexes.

BCL-2 family inhibitors

Anti-apoptotic BCL-2 proteins (BCL-2, BCL-xL BCL-w, MCL-1) bind and sequester pro‐apoptotic effectors (BAX, BAK). BH3 mimetics are small molecules that mimic the BH3 α-helix of pro-apoptotic proteins, binding the hydrophobic groove of anti-apoptotic BCL-2 members and liberating BAX/BAK to induce mitochondrial outer membrane permeabilization.

ABT-737 was the first highly potent BH3 mimetic. Oltersdorf et al. described ABT-737's design via fragment-based NMR screening and structure-guided linkage. ABT-737 binds BCL-2, BCL-xL, and BCL-w with low nanomolar affinity, inducing apoptosis in lymphoma and solid tumor xenografts (Oltersdorf, et al., 2005).

MDM2-p53 inhibitors

Under normal conditions, MDM2 binds p53 and promotes its degradation. In many tumours, MDM2 is overexpressed, leading to the suppression of p53's tumour-suppressor functions. Small molecules that bind the p53-binding pocket of MDM2 prevent this interaction, stabilizing p53 and triggering cell-cycle arrest or apoptosis. One of the first such agents was Nutlin-3a. Vassilev et al. used a structure-guided design to create Nutlin-3a, a potent MDM2 antagonist that activates p53 in cell lines and xenograft models, resulting in tumour growth inhibition in vivo (Lyubomir T et al., 2004). Subsequent optimization yielded more drug-like compounds now in clinical trials.